Atopic dermatitis (AD) is a chronic, inflammatory skin condition with significant patient heterogeneity and links to broader type II inflammatory diseases such as asthma and allergic rhinitis. Understanding disease mechanisms requires precise tools—tissue-specific biomarkers provide quantifiable insights into epidermal and dermal damage, as well as immune cell activity.

Nordic Bioscience’s ProteinFingerPrint Technology™ offers a clinically validated, ECM-focused biomarker platform that enables precise disease characterization, supports targeted therapy development, and facilitates scalable diagnostic solutions. This approach enhances precision medicine by identifying distinct pathological processes and guiding effective, individualized treatment strategies.

Psoriasis is a chronic inflammatory skin disease characterized by keratinocyte hyperproliferation, excessive extracellular matrix remodeling, and increased immune cell activity, resulting in well-demarcated, scaly plaques. The disease shows marked clinical heterogeneity and is associated with systemic inflammation, making accurate assessment of disease activity and progression challenging. Tissue-specific biomarkers may provide objective insights into ongoing inflammation, tissue damage, and remodeling processes.

Nordic Bioscience’s ProteinFingerPrint Technology™ is a clinically validated, ECM-focused biomarker platform designed to support detailed disease characterization and the development of targeted therapies. By capturing key pathological processes involved in inflammation and tissue remodeling, this approach may support improved patient stratification and contribute to more individualized treatment strategies in psoriasis.

Nordic Bioscience integrates translational disease models with ProteinFingerPrint Technology™ to support efficient translation of findings across drug development. By applying the same biomarker readouts throughout preclinical and clinical stages, a continuous link is established between experimental models and clinical applications. Biomarkers are evaluated in preclinical samples, including animal fluids and conditioned media from cellular or explant models, enabling quantitative assessment across systems. This integrated approach enhances the efficiency and translatability of drug development pipelines.